Noninvasive blood–brain barrier integrity mapping in patients with high‐grade glioma and metastasis by multi–echo time–encoded arterial spin labeling
Magnetic Resonance in Medicine · 2025
DOI: 10.1002/mrm.30415 ↗Kurz gefasst
Fachartikel in der Zeitschrift Magnetic Resonance in Medicine, 2025. Verfasst von Gabriel Hoffmann und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Health, Institute for Diagnostic and Interventional Neuroradiology, Technical University of Munich, Munich, Germany. Hauptthemen laut MEDLINE: Brain Neoplasms, Blood-Brain Barrier, Glioma, Magnetic Resonance Imaging. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Evangelisches Studienwerk Villigst Personal Grant to GH, Deutsche Forschungsgemeinschaft, European Union's Horizon 2020 Research and Innovation Program.
Abstract (Originalsprache)
Purpose
In brain tumors, disruption of the blood–brain barrier (BBB) indicates malignancy. Clinical assessment is qualitative; quantitative evaluation is feasible using the K 2 leakage parameter from dynamic susceptibility contrast MRI. However, contrast agent–based techniques are limited in patients with renal dysfunction and insensitive to subtle impairments. Assessing water transport times across the BBB ( T ex ) by multi‐echo arterial spin labeling promises to detect BBB impairments noninvasively and potentially more sensitively. We hypothesized that reduced T ex indicates impaired BBB. Furthermore, we assumed higher sensitivity for T ex than dynamic susceptibility contrast–based K 2 , because arterial spin labeling uses water as a freely diffusible tracer.
Methods
We acquired 3T MRI data from 28 patients with intraparenchymal brain tumors (World Health Organization Grade 3 & 4 gliomas [ n = 17] or metastases [ n = 11]) and 17 age‐matched healthy controls. The protocol included multi‐echo and single‐echo Hadamard‐encoded arterial spin labeling, dynamic susceptibility contrast, and conventional clinical imaging. T ex was calculated using a T 2 ‐dependent multi‐compartment model. Areas of contrast‐enhancing tissue, edema, and normal‐appearing tissue were automatically segmented, and parameter values were compared across volumes of interest and between patients and healthy controls.
Results
T ex was significantly reduced (−20.3%) in contrast‐enhancing tissue compared with normal‐appearing gray matter and correlated well with | K 2 | ( r = −0.347). Compared with healthy controls, T ex was significantly lower in tumor patients' normal‐appearing gray matter ( T ex,tumor = 0.141 ± 0.032 s vs. T ex,HC = 0.172 ± 0.036 s) and normal‐appearing white matter ( T ex,tumor = 0.116 ± 0.015 vs. T ex,HC = 0.127 ± 0.017 s), whereas | K 2 | did not differ significantly. Receiver operating characteristic analysis showed a larger area under the curve for T ex (0.784) than K 2 (0.604).
Conclusion
T ex is sensitive to pathophysiologically impaired BBB. It agrees with contrast agent–based K 2 in contrast‐enhancing tissue and indicates sensitivity to subtle leakage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine and Health, Institute for Diagnostic and Interventional Neuroradiology, Technical University of Munich, Munich, Germany.
- School of Medicine and Health, TUM-Neuroimaging Center, Technical University of Munich, Munich, Germany.
- School of Medicine and Health, Clinic of Neurology, Technical University of Munich, Munich, Germany.
- Fraunhofer Institute for Digital Medicine MEVIS, MR Physics, Bremen, Germany.
- MR-Imaging and Spectroscopy, University of Bremen, Bremen, Germany.
- Mediri, Heidelberg, Germany.
ORCID-Profile: Gabriel Hoffmann, Matthias Günther, Amnah Mahroo, Matthias J P van Osch, Lena Václavů
Förderung
- Evangelisches Studienwerk Villigst Personal Grant to GH
- Deutsche Forschungsgemeinschaft
- European Union's Horizon 2020 Research and Innovation Program
- Philips
- EU Joint Program for Neurodegenerative Disease Research
- Research Foundation - Flanders (FWO)
- Canadian Institutes of Health Research (CIHR)
- BMBF
Zitieren
APA
Hoffmann, G., Preibisch, C., Günther, M., Mahroo, A., van Osch, M. J. P., Václavů, L., Metz, M. C., Jung, K., Zimmer, C., Wiestler, B., & Kaczmarz, S. (2025). Noninvasive blood–brain barrier integrity mapping in patients with high‐grade glioma and metastasis by multi–echo time–encoded arterial spin labeling. Magnetic Resonance in Medicine. https://doi.org/10.1002/mrm.30415
Vancouver
Hoffmann G, Preibisch C, Günther M, Mahroo A, van Osch MJP, Václavů L, et al. Noninvasive blood–brain barrier integrity mapping in patients with high‐grade glioma and metastasis by multi–echo time–encoded arterial spin labeling. Magnetic Resonance in Medicine. 2025. doi:10.1002/mrm.30415
BibTeX
@article{Hoffmann2025,
author = {Hoffmann, Gabriel and Preibisch, Christine and Günther, Matthias and Mahroo, Amnah and van Osch, Matthias J P and Václavů, Lena and Metz, Marie-Christin and Jung, Kirsten and Zimmer, Claus and Wiestler, Benedikt and Kaczmarz, Stephan},
title = {Noninvasive blood–brain barrier integrity mapping in patients with high‐grade glioma and metastasis by multi–echo time–encoded arterial spin labeling},
journal = {Magnetic Resonance in Medicine},
year = {2025},
doi = {10.1002/mrm.30415}
}
EUVIMED